983-P: Long-Term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin—Real-World Data

Objectives: Emerging evidence indicates that CGM use is associated with improvements in glycemic control in adults with noninsulin treated T2D. This real-world study evaluated CGM metrics for one year after CGM initiation in this population. Methods: Data were analyzed from Dexcom G6 and G7 users who self-reported: T2D, ≥18 yr, gender, no insulin use and had baseline TIR ≤70%. Outcomes were change in CGM metrics from baseline to 6 months and 1 year, and proportion with TIR >70% at follow-up overall and for younger (<65 yr) and older (≥65 yr) cohorts. Results: CGM users (n=3,840) were: mean (SD): 52.5 (11.2) yr, 48% female, TIR 70-180 mg/dL 41.7% (21.4) and 12.4% of participants were ≥65 yr. Significant improvement was observed at 6 months with continued improvement at 1 year (Table) for all CGM metrics not at target values at baseline. The proportion of CGM users meeting TIR >70% increased from 0% to 37.9% at 6 months and to 43.1% at 1 year. CGM was worn 84.7% of days. Outcomes were very similar for younger and older adults. One exception of note was the change in the TITR 70-140 mg/dL at 1 year, <65 yr: +17.1% and ≥65 yr: +12.7%, but the <65 yr group started with a lower baseline TITR. Conclusion: In this large, real-world study of adults with suboptimally controlled T2D not using insulin, CGM use was associated with meaningful improvements in glycemic control at 6 months with ongoing improvement at 1 year. Disclosure J.E. Layne: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. Employee; Verily Life Sciences. L.H. Jepson: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. A. Carite: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S.